Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris

A Phase 2a Randomized, Double-blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Effects Of PF-05175157 On Moderate To Severe Acne Vulgaris In Adult Subjects

This is a 6 week study to characterize the safety, tolerability and effects of PF-05175157 administered for 6 weeks in subjects with moderate to severe acne vulgaris.

Inclusion Criteria:

• Males 18 years or older diagnosed with moderate to severe acne vulgaris who are otherwise healthy.
• Normal spirometry at screening (FEV1 and FVC (Forced Vital Capacity)at least 80% predicted).
• Minimum of 20 inflammatory lesions on the face.
• Willing to discontinue other acne treatments prior to and during the study period through follow-up.

Exclusion Criteria:

• Subjects with active nodulocystic acne.
• Subjects unwilling to comply with lifestyle guidelines, commit to study visits, and perform study procedures.
• History of dry eye or other known disease that affects the sclera or cornea.
• History of pulmonary disease or inability to adequately perform testing.